Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 2973 • 2017 ACR/ARHP Annual Meeting
Detection of Clinical Signs of Arthritis and Subclinical Evidence of Inflammation in Psoriasis Patients with Risk for Arthritis: Value of Clinical Examination, Ultrasound and Fluorescence-Optical Imaging – Results from the Prospective Multicentre Xciting Study
Michaela Koehm¹, Tanja Rossmanith², Hans-Eckhard Langer³, Marina Backhaus⁴, Gerd R. Burmester⁵, Siegfried Wassenberg⁶, Benjamin Köhler⁶, Harald Burkhardt⁷ and Frank Behrens⁸, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ³RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, ⁴Rheumatology, Park-Klinik Weissensee, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ⁶Rheumazentrum Ratingen, Ratingen, Germany, ⁷Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁸Clinical Research Rheumatology and Fraunhofer Institute IMETranslation, Goethe University, Frankfurt, Germany
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the…
Abstract Number: 597 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors
Arthur Kavanaugh¹, Helena Marzo-Ortega², Ronald Vender³, Julie Birt⁴, David Adams⁴, Olivier Benichou⁴, Chen-Yen Lin⁴ and Peter Nash⁵, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ³Dermatrials Research, Inc., Hamilton, ON, Canada, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. Up to 24 weeks, IXE was superior to placebo (PBO) in improving…
Abstract Number: 607 • 2017 ACR/ARHP Annual Meeting
Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials
Philip J Mease¹, Mark Lebwohl², Isabelle Gilloteau³, Todd Fox³, Jaime Oliver³, Steffen Jugl³ and Alice B Gottlieb⁴, ¹University of Washington School of Medicine and Swedish Medical Center, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Novartis Pharma AG, Basel, Switzerland, ⁴Department of Dermatology, New York Medical College, Vallhalla, NY
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody selectively neutralizing interleukin-17A, exhibits significant efficacy, with a favorable safety profile, in the treatment of psoriatic arthritis…
Abstract Number: 36 • 2017 Pediatric Rheumatology Symposium
The Association of Obesity with Pediatric Psoriatic Arthritis
Cynthia Manos¹, Rui Xiao², Timothy G. Brandon¹, Alexis Ogdie-Beatty³ and Pamela Weiss⁴, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Obesity is associated with a significantly increased risk of inflammatory arthritis in adult patients with psoriasis. Obese adults with psoriatic arthritis (PsA) also…
Abstract Number: 1709 • 2016 ACR/ARHP Annual Meeting
Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis
Alan J. Kivitz¹, Kim Papp², Alim Devani³, Andreas Pinter⁴, Rodney Sinclair^5,6,7, Michael Ziv⁸, John Caminis⁹, Cass Kelleher¹⁰, Helen Tang¹¹, Barbara Finck¹⁰ and RaPsOdy study group , ¹Altoona Center for Clinical Research, Duncansville, PA, ²K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ³Institute for Skin Advancement, Surgical and Cosmetic Dermatology, Calgary, AB, Canada, ⁴Dept. of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, Frankfurt, Germany, ⁵University of Melbourne, E. Melbourne, Australia, ⁶Epworth Healthcare, E. Melbourne, Australia, ⁷Sinclair Dermatology Investigational Research, Education and Clinical Trials, E. Melbourne, Australia, ⁸Dept of Dermatology, Emek Medical Center, Afula, Israel, ⁹Shire, cambridge, MA, ¹⁰Clinical Science, Coherus BioSciences, Redwood City, CA, ¹¹Coherus BioSciences, Redwood City, CA
Background/Purpose: CHS-0214 is a proposed biosimilar of etanercept, a fusion protein inhibiting tumor necrosis factor. This Phase III multi-center study compared the efficacy and safety…
Abstract Number: 1715 • 2016 ACR/ARHP Annual Meeting
ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A, Does Not Provide Significantly Greater Efficacy Compared with Adalimumab in Subjects with Psoriatic Arthritis: Results from Exposure-Response Analyses
Ben Klunder¹, Amit Khatri², Mukul Minocha³, Paul Peloso⁴ and Ahmed A. Othman², ¹AbbVie, Ludwigshafen am Rhein, Germany, ²AbbVie Inc., North Chicago, IL, ³Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ⁴AbbVie, North Chicago, IL
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Drugs individually neutralizing TNFα or IL-17…
Abstract Number: 1724 • 2016 ACR/ARHP Annual Meeting
The Effect of Certolizumab Pegol on Skin Manifestations of Psoriatic Arthritis over 4 Years of Treatment
Majed Khraishi¹, Alice B. Gottlieb², Bengt Hoepken³, Luke Peterson⁴ and Philip J. Mease⁵, ¹Department of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Tufts University School of Medicine, Boston, MA, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Raleigh, NC, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The majority of patients (pts) with psoriatic arthritis (PsA) experience psoriatic skin manifestations, which add to the already high burden of disease. The RAPID-PsA…
Abstract Number: 1725 • 2016 ACR/ARHP Annual Meeting
Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis
Samy Metyas¹, Ramy Messiah², Tina Gettas², Lisa Asfahani³ and Anne Quismorio⁴, ¹University of Southern California, Keck School of Medicine, Assistant Clinical Professor Of Rheumatology, USC, Covina, CA, ²Research Associate, Covina Arthritis Clinic, covina, CA, ³Physcian Assistant, Covina Arthritis Clinic, Covina, CA, ⁴Rheumatology, Covina Arthritis, Covina, CA
Background/Purpose: Psoriasis is a chronic immune-medicated inflammatory condition that affects 2-3% of the population , which is characterized by rash, silver scaling of the skin…
Abstract Number: 1727 • 2016 ACR/ARHP Annual Meeting
Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis
Benedicte Champs, Rheumatology, Medecine Toulouse Purpan Hospital, Lescure d'albigeois, France
Association between biologic therapies and major adverse cardiac events or cardiac heart failure in psoriatic arthritis or psoriasis: a meta-analysis. 1Champs B, 1Degboe Y, 1Ruyssen-Witrand…
Abstract Number: 2164 • 2016 ACR/ARHP Annual Meeting
Depression and the Risk of Psoriatic Arthritis Among Patients with Psoriasis: A Population-Based Cohort Study
Ryan Lewinson^1,2, Isabelle Vallerand^1,3, Mark Lowerison³, Laurie Parsons⁴, Alexandra Frolkis^1,3, Gilaad Kaplan^3,4, Andrew Bulloch^3,5,6, Scott Patten^3,5 and Cheryl Barnabe^3,4, ¹Leaders in Medicine Program, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Biomedical Engineering Program, Schulich School of Engineering, University of Calgary, Calgary, AB, Canada, ³Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Department of Physiology & Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Depression and the Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-based Cohort Study Background/Purpose: The factors that contribute to the development of psoriatic…
Abstract Number: 72 • 2016 ACR/ARHP Annual Meeting
Longitudinal Expression of CXCL10 in Psoriasis Patients That Develop Psoriatic Arthritis
Fatima Abji¹, Remy Pollock², Kun Liang³, Vinod Chandran⁴ and Dafna D Gladman⁵, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Longitudinal Expression of CXCL10 in Psoriasis Patients that Develop Psoriatic Arthritis Patients Fatima Abji1, Remy Pollock1 Kun Liang2, Vinod Chandran1,3, Dafna D. Gladman1,3 1University of…
Abstract Number: 2171 • 2016 ACR/ARHP Annual Meeting
Increased Rates of Hypertension in Patients with Psoriatic Arthritis Compared to Psoriasis Alone: Results from the UK Biobank
Eftychia Bellou¹, Suzanne M.M. Verstappen², Michael Cook³, Jamie C Sergeant^3,4, Richard B. Warren⁵, Anne Barton^1,4 and John Bowes¹, ¹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁵Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with the presence of psoriasis. Both conditions are influenced by lifestyle factors such as alcohol…
Abstract Number: 149 • 2016 ACR/ARHP Annual Meeting
Comparation of Ultrasonic Imaging of Enthesopathy in the Lower Extremity in Patients with Psoriatic Arthritis, Psoriasis and Other Inflammatory Arthritis
Fei Sun¹ and Jian Zhu², ¹Chinese PLA General Hospital, Beijing, China, ²Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose: To investigate the characteristics and differences of the ultrasonic imaging of enthesopathy in the lower extremity in patients with psoriatic arthritis(PsA), psoriasis(Ps) and other…
Abstract Number: 2443 • 2016 ACR/ARHP Annual Meeting
Pregnancy Comorbidities and Outcomes in Psoriasis and Psoriatic Arthritis: A Prospective Cohort Study
Neda Amiri¹, Gretchen Bandoli² and Christina Chambers², ¹Division of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pediatrics, University of California, San Diego, La Jolla, CA
Pregnancy Comorbidities and Outcomes in Psoriasis and Psoriatic Arthritis: A Prospective Cohort Study Background/Purpose: While there is some evidence that women with psoriasis (Pso) and…
Abstract Number: 937 • 2016 ACR/ARHP Annual Meeting
Distal Interphalangeal Joint Erosions Assessed By HR-pQCT in Patients with Psoriatic Onycholysis
Axel Patrice VILLANI¹, Stéphanie Boutroy², Hubert Marotte Sr.³, Loïs Barets⁴, Marie-Christine Carlier⁵, Roland Chapurlat⁶, Denis Jullien¹ and Cyrille B Confavreux⁷, ¹Dermatology, Hôpital Edouard Herriot, Dermatology department, Lyon I University, Lyon, France, ²Lyon I University, Inserm UMR1033, Lyon, France, ³CHU de St Etienne, Service de rhumatologie, St Etienne, France, ⁴Rheumatology, Hôpital Edouard Herriot, Lyon, France, ⁵Biochemistry, Hôpital Edouard Herriot, Lyon, France, ⁶Rheumatology, Hôpital Edouard Herriot, Hospices Civils de Lyon, University of Lyon, Lyon, France, ⁷Hôpital Edouard Herriot, Hospices Civils de Lyon, University of Lyon, Lyon, France
Background/Purpose: A third of cases of skin psoriasis are complicated by potentially incapacitating psoriatic arthritis (PsA). Nail psoriasis, especially onycholysis, is present in more than…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].